Leerink Partnrs Has Positive Outlook for HALO Q4 Earnings
Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) – Equities researchers at Leerink Partnrs boosted their Q4 2025 earnings estimates for shares of Halozyme Therapeutics in a research note issued to investors on Tuesday, February 18th. Leerink Partnrs analyst D. Risinger now anticipates that the biopharmaceutical company will post earnings per share of $1.66 for the […]
Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) – Equities researchers at Leerink Partnrs boosted their Q4 2025 earnings estimates for shares of Halozyme Therapeutics in a research note issued to investors on Tuesday, February 18th. Leerink Partnrs analyst D. Risinger now anticipates that the biopharmaceutical company will post earnings per share of $1.66 for the […]
